Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CTSL | P07711 | 3/20 | 0.39 |
| ▸ | CTSB | P07858 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5006693 | 0.92 | SLC2A1 (0.44) | SLC2A1KMT2ACTSLCTSBALDH1A1 | |
| SCHEMBL5006687 | 0.91 | SLC2A1 (0.45) | SLC2A1KMT2ACTSLCTSBALDH1A1 | |
| SCHEMBL3930242 | 0.88 | MAOB (0.43) | KMT2AKDM4EMEN1NPC1 | |
| SCHEMBL5007688 | 0.87 | SLC2A1 (0.46) | SLC2A1KMT2ACTSLCTSBALDH1A1 | |
| SCHEMBL3990619 | 0.87 | SLC2A1 (0.46) | SLC2A1KMT2ACTSLCTSBALDH1A1 | |
| Hydrochloric Acid SCHEMBL5006725 | 0.86 | SLC2A1 (0.45) | SLC2A1KMT2ACTSLCTSBALDH1A1 | |
| SCHEMBL5006877 | 0.79 | MAOB (0.46) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5009709 | 0.78 | MAOB (0.45) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5004264 | 0.77 | SLC2A1 (0.48) | SLC2A1POLBSMN1; SMN2 | |
| SCHEMBL10049565 | 0.76 | ALOX5 (0.47) | CTSLCTSBALDH1A1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188089-B2 | Tylophorine analogs as antitumor agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-05-29 | — | — | US | disclosed |
| EP-1968975-A4 | TYLOPHORINE ANALOGS AS ANTITUMOR AGENTS | UNIV NORTH CAROLINA (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080300254-A1 | Tylophorine Analogs as Antitumor Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| EP-1968975-A2 | TYLOPHORINE ANALOGS AS ANTITUMOR AGENTS | The University of North Carolina at Chapel Hill (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007081540-A2 | TYLOPHORINE ANALOGS AS ANTITUMOR AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300254-A1 | Tylophorine Analogs as Antitumor Agents | RPL30, RPL18A, RPP30 | SLC2A1 4242/4885KMT2A 2769/4885CTSL 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.